Opinion

Video

CGM's Impact on Clinical Inertia

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

Video content above is prompted by the following:

  • How does CGM adoption impact clinical inertia and support earlier therapeutic interventions across different patient populations?
  • What measurable improvements have been seen with CGMs in patient outcomes (eg, glycemic control, HbA1c levels, hypoglycemic events, quality of life)?
  • Because each segment is considered a separate entity, each group of discussion questions should reset with No. 1 if using numbers.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
4 experts are featured in this series.
2 experts in this video
4 experts are featured in this series.
Coral Omene, MD, PhD, sitting for a vieo interview
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo